<ul>
<li>該計劃包括組織重組、成本結構優化、外包和銷售支持，以增強競爭力並支持長期戰略。</li>
<li>勞動力優化措施將影響公司約 15% 的員工。</li>
<li>預計 2500 萬美元的年度運營利潤改善中，約 1200 萬美元將在 2026 財年實現。</li>
</ul>
<p>, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) 今天宣佈其全面戰略、運營和組織轉型計劃的第一階段。該階段旨在重新調整組織，以實現更明確的問責制、更嚴格的成本控制和更快速的執行。該計劃還優化了 Accuray 的成本結構，外包部分非核心活動，同時建立內部全球卓越中心，重新分配工程資源，並更好地定位商業組織以推動銷售增長和增強競爭力。一旦全面實施，該階段預計將使運營盈利能力提高約 2500 萬美元，按年化運行率計算。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg"/></p>
<p>該計劃的組織重組部分集中在四個主要領域：簡化 Accuray 的商業結構，集中和全球化核心職能，提升全球服務和產品開發負責人直接向首席執行官彙報的地位，以及優化公司的勞動力和佈局。同時，公司正在外包部分非核心活動，合理化設施，實施提高直接和間接支出效率的項目，並重新分配工程資源，以專注於高投資回報率項目和第三方解決方案的整合。這些措施將全球員工人數減少約 15%，其中薪酬和福利的節省佔預計利潤改善的主要部分，預計在 2026 財年實現約 1200 萬美元，幾乎所有舉措預計將在 2026 財年末全面實施。與該計劃的這一階段相關，公司預計在 2026 財年的第二、第三和第四季度將產生約 1100 萬美元的重組費用，其中大部分為現金，主要與裁員、設施整合、合同終止和其他一次性實施成本相關。Accuray 繼續維持其對 2026 財年全年業績的預測。</p>
<p>&#34;作為一個團隊，我們專注於明確的公司、產品和服務戰略，而第一階段的舉措是由我們在第一財季財報發佈時宣佈的轉型領導者推動的，旨在為該戰略奠定基礎。這些變化使我們在全球每個地區的銷售和服務更加聚焦，建立了更快、更高效的運營節奏，並創造了一個高效、更高利潤的成本結構。所有這些舉措將提高我們的競爭力，確保我們的團隊能夠在每個市場實現增長，坦率地説，使我們成為一家更好的公司。同時，我們對創新、質量、可靠性、客户滿意度和患者護理的承諾仍然至關重要。通過簡化我們的結構，加強問責制，並將資源與戰略影響最大的領域對齊，我們更好地定位自己，繼續為患者、提供者、員工和股東提供卓越價值，&#34; Accuray 首席執行官 Steve La Neve 表示。</p>
<p>Accuray 的戰略貸款合作伙伴 TCW 已通知公司，他們支持公司及其戰略決策，TCW 認為這些決策對加強 Accuray 未來增長的基礎、利潤擴張和長期成功的定位至關重要。</p>
<p>Accuray 預計將在重大進展發生時不時提供有關其轉型計劃的進一步更新。</p>
<p><strong>關於 Accuray</strong> Accuray 致力於擴大放射治療的強大潛力，以改善盡可能多的生命。我們發明獨特的、改變市場的解決方案，旨在為甚至最複雜的病例提供放射治療，同時使常見可治療病例變得更簡單，以滿足患者的全方位需求。我們致力於在腫瘤學、神經放射外科等領域持續創新放射治療，與臨牀醫生和管理人員合作，賦能他們幫助患者更快地恢復生活。Accuray 總部位於威斯康星州麥迪遜，在全球設有設施。要了解更多信息，請訪問 www.accuray.com 或在 Facebook、LinkedIn、X 和 YouTube 上關注我們。</p>
<p><strong>前瞻性聲明</strong> 本新聞稿中所作的非歷史事實的聲明為前瞻性聲明，並受 1995 年《私人證券訴訟改革法案》的 “安全港” 條款的保護。本新聞稿中的前瞻性聲明涉及但不限於公司的未來運營結果，包括以下預期：公司對 2026 財年全年的預測；公司執行並實現其轉型計劃和增長戰略的能力；公司轉型計劃第一階段的舉措，包括時間安排和預期收益；預期的年度運營利潤改善，包括 2026 財年預計的節省；預期的重組費用及其時間安排；公司的競爭力、在其運營市場中實現增長的能力，以及成為一家更好的公司的能力；以及公司為患者、提供者、員工和股東創造價值的能力。這些前瞻性聲明涉及風險和不確定性。如果這些風險或不確定性中的任何一個實現，或者公司的任何假設被證明不正確，實際結果可能與這些前瞻性聲明所表達或暗示的結果有重大差異。這些風險和不確定性包括但不限於公司執行其轉型計劃的能力；全球宏觀經濟環境對公司及其客户和供應商運營的影響；公司供應鏈的中斷，包括物流成本的增加；公司實現其產品廣泛市場接受度的能力；大量未償債務及其維持與債務相關的財務契約合規性的能力；增強國際關税對公司的影響；公司實現中國合資企業及其他合作伙伴關係預期收益的能力；國際運營固有的風險；公司維持或提高產品銷售和服務的毛利率的能力；監管批准或新產品開發或發佈的延遲；公司滿足其信貸設施下契約的能力；公司將積壓訂單轉化為收入的能力；以及在公司於 2025 年 11 月 5 日向證券交易委員會（“SEC”）提交的 10-Q 季度報告中 “風險因素” 標題下識別的其他風險。</p>
<p>前瞻性聲明僅在聲明作出之日有效，並基於公司在作出這些聲明時可獲得的信息和/或管理層在該時刻對未來事件的善意信念。除非適用證券法律要求，否則公司不承擔更新前瞻性聲明以反映實際表現或結果、假設變化或影響前瞻性信息的其他因素變化的義務。因此，投資者不應對任何前瞻性聲明過度依賴。</p>
<p><strong>投資者關係聯繫人</strong> Aman Patel, CFA</p>
<p>投資者關係，ICR Healthcare</p>
<p>aman.patel@ICRHealthcare.com</p>
<p><strong>媒體聯繫人</strong> Megan Brunet</p>
<p>FTI Consulting</p>
<p>Megan.brunet@fticonsulting.com</p>
<p>來源：Accuray Incorporated</p>

精確射線公司

<p>Accuray Incorporated 宣佈了其戰略轉型計劃的第一階段，旨在提高年化運營盈利能力 2500 萬美元。該計劃包括組織重組、成本結構調整、外包和銷售賦能。員工優化將影響 15% 的員工，預計到 2026 財年將節省 1200 萬美元。公司將承擔 1100 萬美元的重組費用。Accuray 的戰略合作伙伴 TCW 支持這些舉措，旨在增強競爭力並支持長期增長</p>

<ul>
<li>Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy.</li>
<li>Workforce optimization actions will affect approximately 15% of the company's employees.</li>
<li>Of the expected $25 million of annualized operating profit improvement, approximately $12 million will be realized in FY2026.</li>
</ul>
<div class="lb-trans"><ul>
<li>該計劃包括組織重組、成本結構優化、外包和銷售支持，以增強競爭力並支持長期戰略。</li>
<li>勞動力優化措施將影響公司約 15% 的員工。</li>
<li>預計 2500 萬美元的年度運營利潤改善中，約 1200 萬美元將在 2026 財年實現。</li>
</ul>
</div><p>, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced the first phase of its comprehensive strategic, operational, and organizational transformation plan. This phase is designed to realign its organization to produce sharper accountability, tighter cost control, and faster execution. The plan also right-sizes Accuray's cost structure, outsources selected non-core activities while building internal global centers of excellence, reallocates engineering resources, and better positions the commercial organization to drive sales growth and enhance competitiveness. Once fully implemented, this phase is expected to improve operating profitability by approximately $25 million on an annualized, run-rate basis.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) 今天宣佈其全面戰略、運營和組織轉型計劃的第一階段。該階段旨在重新調整組織，以實現更明確的問責制、更嚴格的成本控制和更快速的執行。該計劃還優化了 Accuray 的成本結構，外包部分非核心活動，同時建立內部全球卓越中心，重新分配工程資源，並更好地定位商業組織以推動銷售增長和增強競爭力。一旦全面實施，該階段預計將使運營盈利能力提高約 2500 萬美元，按年化運行率計算。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg"/></p>
<p>The organizational realignment element of the plan focuses on four major areas: streamlining Accuray's commercial structure, centralizing and globalizing core functions, elevating the global heads of service and product development to report directly to the CEO, and optimizing the company's workforce and footprint. In parallel, the company is outsourcing selected non-core activities, rationalizing facilities, implementing programs to improve direct and indirect spend efficiency, and reallocating engineering resources to focus on high ROI programs and integration of third party solutions. These actions reduce global headcount by approximately 15%, with savings from compensation and benefits representing the majority of the expected profit improvement, of which roughly $12 million is anticipated to be realized in fiscal 2026, with virtually all initiatives expected to be fully implemented by fiscal 2026 year-end. In connection with this phase of the plan, the Company expects to incur restructuring charges in its fiscal second, third and fourth quarters totaling approximately $11 million, most of it in cash, primarily related to workforce reductions, facility consolidation, contract terminations, and other non-recurring implementation costs. Accuray continues to maintain its forecasts for full year fiscal 2026.</p>
<div class="lb-trans"><p>該計劃的組織重組部分集中在四個主要領域：簡化 Accuray 的商業結構，集中和全球化核心職能，提升全球服務和產品開發負責人直接向首席執行官彙報的地位，以及優化公司的勞動力和佈局。同時，公司正在外包部分非核心活動，合理化設施，實施提高直接和間接支出效率的項目，並重新分配工程資源，以專注於高投資回報率項目和第三方解決方案的整合。這些措施將全球員工人數減少約 15%，其中薪酬和福利的節省佔預計利潤改善的主要部分，預計在 2026 財年實現約 1200 萬美元，幾乎所有舉措預計將在 2026 財年末全面實施。與該計劃的這一階段相關，公司預計在 2026 財年的第二、第三和第四季度將產生約 1100 萬美元的重組費用，其中大部分為現金，主要與裁員、設施整合、合同終止和其他一次性實施成本相關。Accuray 繼續維持其對 2026 財年全年業績的預測。</p>
</div><p>&#34;As a team, we are laser focused on a clear corporate, product and service strategy, and the phase one initiatives, which have been driven by the transformation leaders we announced at the time of our first fiscal quarter earnings release, are designed to set the stage for that strategy. The changes sharpen our focus on sales and service in every region around the world, establish a faster, more efficient operating rhythm, and create an efficient, higher-margin cost structure. All of these initiatives will increase our competitiveness, ensure our teams are poised to deliver growth in each market, and, frankly, make us a better company. At the same time, our commitment to innovation, quality, reliability, customer satisfaction, and patient care remains paramount. By simplifying our structure, strengthening accountability, and aligning resources with the areas of greatest strategic impact, we are better positioned to continue delivering exceptional value to patients, providers, employees, and shareholders,&#34; said Steve La Neve, Chief Executive Officer of Accuray.</p>
<div class="lb-trans"><p>&#34;作為一個團隊，我們專注於明確的公司、產品和服務戰略，而第一階段的舉措是由我們在第一財季財報發佈時宣佈的轉型領導者推動的，旨在為該戰略奠定基礎。這些變化使我們在全球每個地區的銷售和服務更加聚焦，建立了更快、更高效的運營節奏，並創造了一個高效、更高利潤的成本結構。所有這些舉措將提高我們的競爭力，確保我們的團隊能夠在每個市場實現增長，坦率地説，使我們成為一家更好的公司。同時，我們對創新、質量、可靠性、客户滿意度和患者護理的承諾仍然至關重要。通過簡化我們的結構，加強問責制，並將資源與戰略影響最大的領域對齊，我們更好地定位自己，繼續為患者、提供者、員工和股東提供卓越價值，&#34; Accuray 首席執行官 Steve La Neve 表示。</p>
</div><p>Accuray's strategic lending partner TCW has informed the company that they support the company and its strategic decisions, which TCW believes are essential to strengthening Accuray's foundation for future growth, margin expansion, and positioning itself for long-term success.</p>
<div class="lb-trans"><p>Accuray 的戰略貸款合作伙伴 TCW 已通知公司，他們支持公司及其戰略決策，TCW 認為這些決策對加強 Accuray 未來增長的基礎、利潤擴張和長期成功的定位至關重要。</p>
</div><p>Accuray expects to give further updates concerning its transformation plan from time to time as material developments occur.</p>
<div class="lb-trans"><p>Accuray 預計將在重大進展發生時不時提供有關其轉型計劃的進一步更新。</p>
</div><p><strong>About Accuray</strong> Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.</p>
<div class="lb-trans"><p><strong>關於 Accuray</strong> Accuray 致力於擴大放射治療的強大潛力，以改善盡可能多的生命。我們發明獨特的、改變市場的解決方案，旨在為甚至最複雜的病例提供放射治療，同時使常見可治療病例變得更簡單，以滿足患者的全方位需求。我們致力於在腫瘤學、神經放射外科等領域持續創新放射治療，與臨牀醫生和管理人員合作，賦能他們幫助患者更快地恢復生活。Accuray 總部位於威斯康星州麥迪遜，在全球設有設施。要了解更多信息，請訪問 www.accuray.com 或在 Facebook、LinkedIn、X 和 YouTube 上關注我們。</p>
</div><p><strong>Forward-Looking Statements</strong> Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: the company's forecasts for the full year fiscal 2026; the company's ability to execute upon and realize the benefits of its transformation plan and growth strategy; the company's first phase of its transformation plan initiatives, including timing and expected benefits; expected annualized operating profit improvement, including savings anticipated for fiscal year 2026; expected restructuring charges and timing of such charges; the company's competitiveness, ability to deliver growth in the markets in which it operates, and become a better company; and the company's ability to deliver value to patients, providers, employees, and shareholders. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the ability of the company to execute upon its transformation plan; the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to the company's supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading &#34;Risk Factors&#34; in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the &#34;SEC&#34;) on November 5, 2025, and as updated periodically with the company's other filings with the SEC.</p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong> 本新聞稿中所作的非歷史事實的聲明為前瞻性聲明，並受 1995 年《私人證券訴訟改革法案》的 “安全港” 條款的保護。本新聞稿中的前瞻性聲明涉及但不限於公司的未來運營結果，包括以下預期：公司對 2026 財年全年的預測；公司執行並實現其轉型計劃和增長戰略的能力；公司轉型計劃第一階段的舉措，包括時間安排和預期收益；預期的年度運營利潤改善，包括 2026 財年預計的節省；預期的重組費用及其時間安排；公司的競爭力、在其運營市場中實現增長的能力，以及成為一家更好的公司的能力；以及公司為患者、提供者、員工和股東創造價值的能力。這些前瞻性聲明涉及風險和不確定性。如果這些風險或不確定性中的任何一個實現，或者公司的任何假設被證明不正確，實際結果可能與這些前瞻性聲明所表達或暗示的結果有重大差異。這些風險和不確定性包括但不限於公司執行其轉型計劃的能力；全球宏觀經濟環境對公司及其客户和供應商運營的影響；公司供應鏈的中斷，包括物流成本的增加；公司實現其產品廣泛市場接受度的能力；大量未償債務及其維持與債務相關的財務契約合規性的能力；增強國際關税對公司的影響；公司實現中國合資企業及其他合作伙伴關係預期收益的能力；國際運營固有的風險；公司維持或提高產品銷售和服務的毛利率的能力；監管批准或新產品開發或發佈的延遲；公司滿足其信貸設施下契約的能力；公司將積壓訂單轉化為收入的能力；以及在公司於 2025 年 11 月 5 日向證券交易委員會（“SEC”）提交的 10-Q 季度報告中 “風險因素” 標題下識別的其他風險。</p>
</div><p>Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.</p>
<div class="lb-trans"><p>前瞻性聲明僅在聲明作出之日有效，並基於公司在作出這些聲明時可獲得的信息和/或管理層在該時刻對未來事件的善意信念。除非適用證券法律要求，否則公司不承擔更新前瞻性聲明以反映實際表現或結果、假設變化或影響前瞻性信息的其他因素變化的義務。因此，投資者不應對任何前瞻性聲明過度依賴。</p>
</div><p><strong>Investor Relations Contact</strong> Aman Patel, CFA</p>
<div class="lb-trans"><p><strong>投資者關係聯繫人</strong> Aman Patel, CFA</p>
</div><p>Investor Relations, ICR Healthcare</p>
<div class="lb-trans"><p>投資者關係，ICR Healthcare</p>
</div><p>aman.patel@ICRHealthcare.com</p>
<div class="lb-trans"><p>aman.patel@ICRHealthcare.com</p>
</div><p><strong>Media Contact</strong> Megan Brunet</p>
<div class="lb-trans"><p><strong>媒體聯繫人</strong> Megan Brunet</p>
</div><p>FTI Consulting</p>
<div class="lb-trans"><p>FTI Consulting</p>
</div><p>Megan.brunet@fticonsulting.com</p>
<div class="lb-trans"><p>Megan.brunet@fticonsulting.com</p>
</div><p>SOURCE Accuray Incorporated</p>
<div class="lb-trans"><p>來源：Accuray Incorporated</p>
</div>

Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by  approximately $25 million and set the stage for renewed growth | ARAY Stock News

精確射線公司宣佈了全面戰略、運營和組織轉型計劃的第一階段；公司預計該階段將使年度化運營盈利能力提高約 2500 萬美元，併為重新實現增長奠定基礎 | ARAY 股票新聞